Tenaya Therapeutics (TNYA) Total Non-Current Liabilities (2020 - 2026)
Tenaya Therapeutics (TNYA) posted quarterly Total Non-Current Liabilities of $28.5 million for Q1 2026, up 17.28% year-over-year from $24.3 million in Q1 2025, and up 22.44% quarter-over-quarter from $23.2 million in Q4 2025.
Tenaya Therapeutics (TNYA) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends
Tenaya Therapeutics' Total Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $28.5 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 17.28% year-over-year to $28.5 million; the TTM figure through Mar 2026 stood at $28.5 million (up 17.28% YoY), while the FY2025 annual figure was $23.2 million, down 13.28% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $28.5 million, up from $23.2 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $35.3 million in Q4 2022, with the low at $21.8 million in Q3 2025.
- The 5-year median for Total Non-Current Liabilities is $28.5 million (2026), against an average of $28.1 million.
- The sharpest annual moves came in 2022 and 2025: Total Non-Current Liabilities increased 28.96% in 2022, then slipped 23.83% in 2025.
- Tenaya Therapeutics' Total Non-Current Liabilities stood at $35.3 million in 2022, then retreated by 12.74% to $30.8 million in 2023, then dropped by 13.08% to $26.8 million in 2024, then dropped by 13.28% to $23.2 million in 2025, then advanced by 22.44% to $28.5 million in 2026.
- Business Quant data shows TNYA's Total Non-Current Liabilities at $28.5 million in Q1 2026, $23.2 million in Q4 2025, and $21.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | Tenaya Therapeutics | 151.50 Mn | 151.50 Mn | - | 24.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 24.03 Mn |
| Mar 31, 2026 | 28.46 Mn |
| Dec 31, 2025 | 23.25 Mn |
| Sep 30, 2025 | 21.81 Mn |
| Jun 30, 2025 | 22.03 Mn |
| Mar 31, 2025 | 24.27 Mn |
| Dec 31, 2024 | 26.81 Mn |
| Sep 30, 2024 | 27.70 Mn |
| Jun 30, 2024 | 28.92 Mn |
| Mar 31, 2024 | 26.46 Mn |
| Dec 31, 2023 | 30.84 Mn |
| Sep 30, 2023 | 28.27 Mn |
| Jun 30, 2023 | 30.57 Mn |
| Mar 31, 2023 | 29.70 Mn |
| Dec 31, 2022 | 35.34 Mn |
| Sep 30, 2022 | 29.76 Mn |
| Jun 30, 2022 | 31.85 Mn |
| Mar 31, 2022 | 32.19 Mn |
| Dec 31, 2021 | 35.48 Mn |
| Sep 30, 2021 | 28.00 Mn |